APO RESEARCH · REPORT
Neurological Biomarkers
A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention. Examples of classical biomarkers are measurable alterations in blood pressure and blood glucose in diabetes mellitus.
Product & engineering
Understand the product.
A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention. Examples of classical biomarkers are measurable alterations in blood pressure and blood glucose in diabetes mellitus.
Selected research
Industry Research
Neurological Biomarkers Industry Research Report 2026
Market perspective
A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention. Examples of classical biomarkers are measurable alterations in blood pressure and blood glucose in diabetes mellitus.
Global Neurological Biomarkers key players include Thermo Fisher Scientific, Merck, Quest Diagnostics, Abbott, etc. Global top four manufacturers hold a share about 25%.
North America is the largest market, with a share over 55%, followed by Europe, and Asia-Pacific, both have a share over 35 percent.
Read the full market overview
In terms of product, Proteomics is the largest segment, with a share about 30%. And in terms of application, the largest application is Proteomics, followed by Drug Discovery, Personalized Medicine, etc.
Report Scope
This report quantifies the global Neurological Biomarkers market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neurological Biomarkers Market by Company
Thermo Fisher Scientific
Merck
Quest Diagnostics
Abbott
Roche
Illumina
Bio-Rad Laboratories
QIAGEN
Myriad RBM
Cisbio Bioassays
Athena Diagnostics
BGI
Wuxi APP
Aepodia
Proteome Sciences
Genewiz
Neurological Biomarkers Segment by Type
Proteomics
Genomics
Imaging
Bioinformatics
Others
Neurological Biomarkers Segment by Application
Diagnostics
Drug Discovery
Personalized Medicine
Others
Neurological Biomarkers Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurological Biomarkers market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurological Biomarkers and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurological Biomarkers.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Neurological Biomarkers manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Neurological Biomarkers by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Neurological Biomarkers in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Proteomics
- Genomics
- Imaging
- Bioinformatics
- Others
Applications
- Diagnostics
- Drug Discovery
- Personalized Medicine
- Others
Companies covered
- Thermo Fisher Scientific
- Merck
- Quest Diagnostics
- Abbott
- Roche
- Illumina
- Bio-Rad Laboratories
- QIAGEN
- Myriad RBM
- Cisbio Bioassays
- Athena Diagnostics
- BGI
- Wuxi APP
- Aepodia
- Proteome Sciences
- Genewiz
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Neurological Biomarkers Market Size (2021-2032)
- 2.2.2 Global Neurological Biomarkers Sales (2021-2032)
- 2.2.3 Global Neurological Biomarkers Market Average Price (2021-2032)
- 2.3 Neurological Biomarkers by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Proteomics
- 2.3.3 Genomics
- 2.3.4 Imaging
- 2.3.5 Bioinformatics
- 2.3.6 Others
- 2.4 Neurological Biomarkers by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Diagnostics
- 2.4.3 Drug Discovery
- 2.4.4 Personalized Medicine
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Neurological Biomarkers Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Neurological Biomarkers Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Neurological Biomarkers Revenue of Manufacturers (2021-2026)
- 3.4 Global Neurological Biomarkers Average Price by Manufacturers (2021-2026)
- 3.5 Global Neurological Biomarkers Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Neurological Biomarkers, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Neurological Biomarkers, Product Type & Application
- 3.8 Global Manufacturers of Neurological Biomarkers, Established Date
- 3.9 Global Neurological Biomarkers Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Thermo Fisher Scientific
- 4.1.1 Thermo Fisher Scientific Company Information
- 4.1.2 Thermo Fisher Scientific Business Overview
- 4.1.3 Thermo Fisher Scientific Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Thermo Fisher Scientific Neurological Biomarkers Product Portfolio
- 4.1.5 Thermo Fisher Scientific Recent Developments
- 4.2 Merck
- 4.2.1 Merck Company Information
- 4.2.2 Merck Business Overview
- 4.2.3 Merck Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck Neurological Biomarkers Product Portfolio
- 4.2.5 Merck Recent Developments
- 4.3 Quest Diagnostics
- 4.3.1 Quest Diagnostics Company Information
- 4.3.2 Quest Diagnostics Business Overview
- 4.3.3 Quest Diagnostics Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Quest Diagnostics Neurological Biomarkers Product Portfolio
- 4.3.5 Quest Diagnostics Recent Developments
- 4.4 Abbott
- 4.4.1 Abbott Company Information
- 4.4.2 Abbott Business Overview
- 4.4.3 Abbott Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Abbott Neurological Biomarkers Product Portfolio
- 4.4.5 Abbott Recent Developments
- 4.5 Roche
- 4.5.1 Roche Company Information
- 4.5.2 Roche Business Overview
- 4.5.3 Roche Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Roche Neurological Biomarkers Product Portfolio
- 4.5.5 Roche Recent Developments
- 4.6 Illumina
- 4.6.1 Illumina Company Information
- 4.6.2 Illumina Business Overview
- 4.6.3 Illumina Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Illumina Neurological Biomarkers Product Portfolio
- 4.6.5 Illumina Recent Developments
- 4.7 Bio-Rad Laboratories
- 4.7.1 Bio-Rad Laboratories Company Information
- 4.7.2 Bio-Rad Laboratories Business Overview
- 4.7.3 Bio-Rad Laboratories Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bio-Rad Laboratories Neurological Biomarkers Product Portfolio
- 4.7.5 Bio-Rad Laboratories Recent Developments
- 4.8 QIAGEN
- 4.8.1 QIAGEN Company Information
- 4.8.2 QIAGEN Business Overview
- 4.8.3 QIAGEN Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 QIAGEN Neurological Biomarkers Product Portfolio
- 4.8.5 QIAGEN Recent Developments
- 4.9 Myriad RBM
- 4.9.1 Myriad RBM Company Information
- 4.9.2 Myriad RBM Business Overview
- 4.9.3 Myriad RBM Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Myriad RBM Neurological Biomarkers Product Portfolio
- 4.9.5 Myriad RBM Recent Developments
- 4.10 Cisbio Bioassays
- 4.10.1 Cisbio Bioassays Company Information
- 4.10.2 Cisbio Bioassays Business Overview
- 4.10.3 Cisbio Bioassays Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Cisbio Bioassays Neurological Biomarkers Product Portfolio
- 4.10.5 Cisbio Bioassays Recent Developments
- 4.11 Athena Diagnostics
- 4.11.1 Athena Diagnostics Company Information
- 4.11.2 Athena Diagnostics Business Overview
- 4.11.3 Athena Diagnostics Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Athena Diagnostics Neurological Biomarkers Product Portfolio
- 4.11.5 Athena Diagnostics Recent Developments
- 4.12 BGI
- 4.12.1 BGI Company Information
- 4.12.2 BGI Business Overview
- 4.12.3 BGI Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 BGI Neurological Biomarkers Product Portfolio
- 4.12.5 BGI Recent Developments
- 4.13 Wuxi APP
- 4.13.1 Wuxi APP Company Information
- 4.13.2 Wuxi APP Business Overview
- 4.13.3 Wuxi APP Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Wuxi APP Neurological Biomarkers Product Portfolio
- 4.13.5 Wuxi APP Recent Developments
- 4.14 Aepodia
- 4.14.1 Aepodia Company Information
- 4.14.2 Aepodia Business Overview
- 4.14.3 Aepodia Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Aepodia Neurological Biomarkers Product Portfolio
- 4.14.5 Aepodia Recent Developments
- 4.15 Proteome Sciences
- 4.15.1 Proteome Sciences Company Information
- 4.15.2 Proteome Sciences Business Overview
- 4.15.3 Proteome Sciences Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Proteome Sciences Neurological Biomarkers Product Portfolio
- 4.15.5 Proteome Sciences Recent Developments
- 4.16 Genewiz
- 4.16.1 Genewiz Company Information
- 4.16.2 Genewiz Business Overview
- 4.16.3 Genewiz Neurological Biomarkers Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Genewiz Neurological Biomarkers Product Portfolio
- 4.16.5 Genewiz Recent Developments
5 Global Neurological Biomarkers Market Scenario by Region
- 5.1 Global Neurological Biomarkers Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Neurological Biomarkers Sales by Region: 2021-2032
- 5.2.1 Global Neurological Biomarkers Sales by Region: 2021-2026
- 5.2.2 Global Neurological Biomarkers Sales by Region: 2027-2032
- 5.3 Global Neurological Biomarkers Revenue by Region: 2021-2032
- 5.3.1 Global Neurological Biomarkers Revenue by Region: 2021-2026
- 5.3.2 Global Neurological Biomarkers Revenue by Region: 2027-2032
- 5.4 North America Neurological Biomarkers Market Facts & Figures by Country
- 5.4.1 North America Neurological Biomarkers Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Neurological Biomarkers Sales by Country (2021-2032)
- 5.4.3 North America Neurological Biomarkers Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Neurological Biomarkers Market Facts & Figures by Country
- 5.5.1 Europe Neurological Biomarkers Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Neurological Biomarkers Sales by Country (2021-2032)
- 5.5.3 Europe Neurological Biomarkers Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Neurological Biomarkers Market Facts & Figures by Country
- 5.6.1 Asia Pacific Neurological Biomarkers Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Neurological Biomarkers Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Neurological Biomarkers Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Neurological Biomarkers Market Facts & Figures by Country
- 5.7.1 South America Neurological Biomarkers Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Neurological Biomarkers Sales by Country (2021-2032)
- 5.7.3 South America Neurological Biomarkers Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Neurological Biomarkers Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Neurological Biomarkers Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Neurological Biomarkers Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Neurological Biomarkers Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Neurological Biomarkers Sales by Type (2021-2032)
- 6.1.1 Global Neurological Biomarkers Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Neurological Biomarkers Sales Market Share by Type (2021-2032)
- 6.2 Global Neurological Biomarkers Revenue by Type (2021-2032)
- 6.2.1 Global Neurological Biomarkers Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Neurological Biomarkers Revenue Market Share by Type (2021-2032)
- 6.3 Global Neurological Biomarkers Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Neurological Biomarkers Sales by Application (2021-2032)
- 7.1.1 Global Neurological Biomarkers Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Neurological Biomarkers Sales Market Share by Application (2021-2032)
- 7.2 Global Neurological Biomarkers Revenue by Application (2021-2032)
- 7.2.1 Global Neurological Biomarkers Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Neurological Biomarkers Revenue Market Share by Application (2021-2032)
- 7.3 Global Neurological Biomarkers Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Neurological Biomarkers Value Chain Analysis
- 8.1.1 Neurological Biomarkers Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Neurological Biomarkers Production Mode & Process
- 8.2 Neurological Biomarkers Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Neurological Biomarkers Distributors
- 8.2.3 Neurological Biomarkers Customers
9 Global Neurological Biomarkers Analyzing Market Dynamics
- 9.1 Neurological Biomarkers Industry Trends
- 9.2 Neurological Biomarkers Industry Drivers
- 9.3 Neurological Biomarkers Industry Opportunities and Challenges
- 9.4 Neurological Biomarkers Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst